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Abstract: Kidney cancer rapidly acquires resistance to antiangiogenic agents, such as sunitinib,
developing an aggressive migratory phenotype (facilitated by c-Metsignal transduction). The Aryl
hydrocarbon receptor (AhR) has recently been postulated as a molecular target for cancer treatment.
Currently, there are two antitumor agent AhR ligands, with activity against renal cancer, that have
been tested clinically: aminoflavone (AFP 464, NSC710464) and the benzothiazole (5F 203) prodrug
Phortress. Our studies investigated the action of AFP 464, the aminoflavone pro-drug currently used
in clinical trials, and 5F 203 on renal cancer cells, specifically examining their effects on cell cycle
progression, apoptosis and cell migration. Both compounds caused cell cycle arrest and apoptosis but
only 5F 203 potently inhibited the migration of TK-10, Caki-1 and SN12C cells as well as the migration
signal transduction cascade, involving c-Met signaling, in TK-10 cells. Current investigations are
focused on the development of nano-delivery vehicles, apoferritin-encapsulated benzothiazoles 5F
203 and GW610, for the treatment of renal cancer. These compounds have shown improved antitumor
effects against TK-10 cells in vitro at lower concentrations compared with a naked agent.
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1. Introduction
1.1. Renal Cancer Background
Renal cell carcinoma (RCC) is the sixth most common malignancy in men and tenth in women
worldwide with a significant variation in incidence and mortality between different geographic
regions. Incidence rates are highest in North America followed by Europe and Australia. The highest
estimated mortality rates have been observed in Uruguay, Argentina, Chile and the USA [1]. Current
histopathological classification of renal tumors totals more than ten histopathological and molecular
subtypes of carcinomas. Clear cell renal cell carcinoma (ccRCC, near 75%), papillary renal cell carcinoma
(type I and type II) and chromophobe renal cell carcinoma are the most common of them. Remaining
subtypes are infrequent and account for less than 1% each [2].
Certain correlation between histopathologic subtypes and genomic alteration in the main RCC
subtypes can be traced. Bi-allelic loss of function of the Von Hippel Lindau (VHL) tumor suppressor
gene, as a consequence of mutations, deletions or epigenetic silencing, is found in the vast majority of
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ccRCC and is usually the most precocious truncal molecular driving event [2]. However, additional
mutations, including PBRM1 (polibrome-1), SETD2 (SET Domain Containing 2), BAP1 (BRCA1
associated protein 1) and PI3K-AKT-mTOR, are usually needed for aggressive malignant phenotypes
to arise. Type I papillary RCC is characterized by proto-oncogene c-Met over-expression/amplification
as a result of activated mutations or copy number alterations [3,4]. It has recently been described that
aryl hydrocarbon receptor (AhR) activation mediates kidney disease and renal cell carcinoma [5].
1.2. Current Therapies_ENREF_7_ENREF_4
At present, two categories of pharmacological treatment options for metastatic/advanced RCC
are supported by relevant clinical practice guidelines: targeted therapies and immune therapies [6–8]
_ENREF_9. The targeted therapies include vascular endothelial growth factor receptor tyrosine-kinase
inhibitors (VEGFR TKIs) and rapalogues, which inhibit the mammalian target of the rapamycin (mTOR)
pathway signaling. This therapy aims to override the effects of hypoxia-inducible growth factor
activation. ”Classic” antiangiogenic agents (sorafenib, sunitinib, pazopanib, axitinib, bevacizumab)
target the VEGF pathway, while more recently approved cabozantinib and lenvatinib also act upon the
compensatory activation of putative resistance mechanisms, such as hepatocyte growth factor and
fibroblast growth factor activation [3,4].
Immune check-point inhibitors (ICIs) are by far the most important subclass among the
immunotherapy drugs. The use of cytokines interleukine-2 and interferon-alpha has largely declined [9].
Ipilimumab is a monoclonal antibody, which antagonizes CTLA-4 and selectively depletes T-regs
in the tumor microenvironment, stimulating an anti-tumor immune response [10,11]. Monoclonal
antibodies directed against programmed death receptor-1 (PD-1), e.g., nivolumab and pembrolizumab,
and its ligand (PD-L1) Avelumab, inhibit the immunosuppressive co-signals mediated by PD-1/PD-L1
interaction, enhancing the anti-tumor activity of the T-cells [12].
Recently, several Phase 3 studies demonstrated that combinations of drugs are more efficacious
compared to single agents, suggesting that combining agents with different mechanisms of action
could offer a promising route to overcome tumor resistance and improve survival outcomes. However,
overlapping toxicities have been encountered and merit further investigation [13–15]. Since added
toxicities may limit the use of synergistic combinations in cancer treatments, there is an urgent demand
for new active agents with a completely distinct mechanism(s) of action. In this review, we discuss the
role of the AhR ligands aminoflavone and benzothiazoles as potential new agents for the treatment of
advanced mRCC.
2. Aryl Hydrocarbon Receptor
The aryl hydrocarbon receptor (AhR) was initially identified as a receptor for environmental
toxins, such as dioxin. It belongs to the helix–loop–helix transcription factor family. Other members
of this family are the AhR nuclear translocator (ARNT), the SIM and PER proteins as well as
hypoxia-inducible factor 1α(HIF 1α) [16–19]. AhR is a ligand-activated transcription factor. The first
described ligands of AhR were exogenous: polycyclic and polyhalogenated hydrocarbons (benzopyrene,
3-methyl-colantrene), xenobiotics (phenobarbital) and other pesticides like tetrachlorodibenzo-p-dioxin
(TCDD) [19].
AhR is localized within the cell cytosol constitutively, where it is part of an inactivated complex
composed of heat-shock protein 90 (Hsp90) and a 43 kDa protein known as AIP (Figure 1). The role of
Hsp90 involves a chaperone activity that keeps AhR in a ligand-binding configuration and prevents its
nuclear translocation. Hydrophobic ligands of AhR enter the cell by diffusion and bind to the receptor
associated with Hsp90. This event leads to dissociation of the cytoplasmic complex and to AhR nuclear
translocation. Within the nucleus, AhR interacts with the aryl hydrocarbon nuclear transporter (ARNT)
forming a heterodimer that binds to specific DNA sequences called xenobiotic response elements
(XREs). This binding leads to the transcriptional activation of genes that possess these XREs in their
promoter sequences. Some of the genes activated by AhR encode Phase I and II metabolic enzymes,
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such as cytochrome P450 (CYP) 1A1, CYP1A2 and CYP1B1. Transgenic mice with a constitutively
active AhR spontaneously develop tumors and the repressor of the AhR (AHRR) functions as a
tumor suppressor in multiple human tumors. The expression of this gene is activated by AhR.
The AHHR is known to competitively dimerize with ARNT, repressing AhR activity. The expression
of AAHR has been correlated with metastasis-free survival in breast cancers [20,21]. In addition,
AhR forms as a Cul4B-based E3 ubiquitin ligase complex, inducing selective protein degradation.
AhR regulation signaling can be controlled via nuclear export and subsequent AhR degradation
through the ubiquitin–proteasome signaling pathway [22]. In addition to this canonical pathway,
signaling through AhR can also be mediated through interactions with other regulatory proteins,
such as estrogen. AhR interacts with multiple other signaling pathways and activates other cytosolic
proteins, including β-catenin, Smads, ERK, p38MAPK, JNK, NF-κB and RB [23].
AhR activation was first described as a cellular response to promote elimination of ambient
contaminants and xenobiotics [24–26]. In humans, AhR is localized in the liver, lungs, kidneys, placenta,
lymphocytes, ovary and breast. AhR/ARNT complex activation is tissue-specific and depends on
co-regulators being present in different cell types [25]. Only a few endogenous AhR ligands have been
reported. The prostaglandins (e.g., prostaglandin G2) are of note weak AhR agonist. Bilirubin [27]
and prostaglandin G2 [28] are considered atypical AhR ligands, lacking the usual small, aromatic,
rigid compounds.
Naturally occurring polyphenolic compounds, known as flavonoids (flavones, flavonols and
isoflavones), are substrates of CYP1A1 and CYP1B1, and are present in vegetables, fruits, medicinal
herbs, beverages and dietary supplements [29]. Flavonoid compounds represent the largest class of
natural AhR ligands [30]. This is an interesting and promising field of research for nutraceuticals in
antitumor therapy whose molecular target is AhR.
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2.1. Aminoflavone and Benzothiazoles: AhR-Targeted Antitumor Therapies
The flavone analogue aminoflavone (AF) (4H-1-benzopyran-4-one, 5-amino-2-(4-amino-3-
fluorophenyl)-6,8-difluoro-7-methyl) (NSC 686288, KyowaHakko Kogyo Co., Ltd., Tokyo, Japan)
(Figure 2) has emerged as a candidate for preclinical evaluation and advancement to Phase I clinical
trials, based on demonstrable antitu or activity in mice bearing human tumor xenografts and in
the United States National Cancer Institute anticancer drug screen. Human tumor cell lines that
exhibited particular sensitivity to AF include those of breast and renal origin. AF treatment of sensitive
human MCF-7 breast tumor cells revealed elevated CYP1A1/1A2 protein levels [31]. Preclinically,
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the antitumor benzothiazoles 5F 203 and Phortress (Figure 2) evoked potent antiproliferative activity
in breast and ovarian tumor models, inducing CYP1A1 expression and generating DNA adducts,
which are converted to lethal strand breaks in sensitive cell lines and xenografts only [26,32].
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2.2. Sensitivity of Renal Cell Carcinoma to Aminoflavone: Role of CYP1A1
In an effort to delineate cellular markers of sensitivity to AF in cells of renal origin, we performed
investigations on established renal cell lines and a series of renal cell isolates from patients with
confirmed clear cell and papillary renal disease.
In vitro antiproliferative activity of AF was evaluated in the cell lines Caki-1, TK-10, A498,RXF-393,
ACHN and SN12-C (National Cancer Institute (NCI) repository, NCI-Frederick, Frederick, Maryland),
grown as described [33,34]. Briefly, for these studies cells were seeded into 24-well plates, allowed
to grow for 48 h and treated with AF (10−10 to 10−5 M) for 72 h. Drug exposure was terminated
by the addition of 50% trichloroacetic acid to a final 10% concentration. Cells were stained with
sulforhodamine B and protein was determined spectrophotometrically. Values are shown as the
mean ± SD of 10 preparations [35]. AF produced 100% (total) growth inhibition at sub-micromolar
concentrations after 72 h exposure in 3 of the 6 renal cell lines used. Caki-1 was the renal cell line most
sensitive to AF with the drug producing total growth inhibition at 90 nM. Two other cell lines, A498
and TK-10, were also sensitive to AF, with growth inhibition at AF concentrations of 200 and 400 nM,
respectively. AF produced in vitro regression in each of these AF sensitive cell lines, as evidenced
by the drug-induced loss of cellular protein during the treatment period. Three additional cell lines
(ACHN, SN12-C and RXF-393) were judged AF resistant, since total growth inhibition was not achieved
even at an AF concentration of 10 µM.
2.3. Effect of AF on Human Tumor Renal Xenografts
The Caki-1 human tumor xenograft was established as described [36,37]. Intraperitoneal (IP) and
intravenous (IV) treatments were given on a QD X 5 schedule, beginning Day 13. AF treatment of mice
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bearing Caki-1 renal cell carcinoma produced 100% (6 of 6) tumor-free survivors at intraperitoneal
120, 80 and 53 mg/kg doses, and 2 of the 6 tumor-free survivors at 90 mg/kg intravenously. Values are
reported as the mean ± SD in 20 vehicle controls and 6 animals per AF dose (Figure 3). In contrast,
AF demonstrated negligible activity and produced no tumor-free survivors against the AF-resistant
RXF-393 tumor (data not shown). It was noteworthy that a single course of treatment during 5 days
had a lasting impact after a subsequent 6 to 7 weeks in the responsive Caki-1 model [33].
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(Figure reproduced from [33]).
2.4. AF Sensitivity and Induction of CYP1A1 and CYP1B1 mRNA
AF induced CYP1A1 and CYP1B1 gene expression in human tumor renal cell lines. Human
tumor renal cell lines were treated with 1 to 1000 nM AF for 24 h. RNA was isolated from the control
and treated samples, and CYP1A1 and CYP1B1 gene expression was measured by real-time RT-PCR,
as described [33]. Data are shown as the mean fold induction of the treated cells ± SD relative to the
constitutive expression in the control cells in 7 samples from 2 independent experiments.
2.5. AF Induced Apoptosis in AF Sensitive Renal Tumor Cell Lines
AF induced apoptosis in AF sensitive human tumor renal cell lines. Apoptosis was quantified
following exposure to 1 µM AF for 24 h using M30-Apoptosense kit, as described [33]. Values were
represented as the mean ± SD of 3 preparations, as described [33].
AF treatment resulted in an over 10-fold increase in apoptosis in Caki-1 and A498, the two most
sensitive renal cell lines, and an over 6-fold increase in apoptosis in TK-10, the other AF-sensitive renal
cell line. In contrast, AF treatment of RXF-393 and ACHN, the two most AF-resistant cell lines, did not
result in apoptosis induction.
2.6. AF Sensitivity and Covalent Binding in Human Renal Cell Strains
The preceding observations in continuous cell cultures prompted a parallel series of investigations
using r nal cell carcinoma isolate (termed renal cell strains) obtained from patients diagnosed with
papillary and clear cell renal carcinoma undergoing therapeutic protocols at the NCI Urologic Oncology
Bra ch. All patient-derived material was obtained after appropriate informed consent [33]. T ese cell
is lates were used in attempt to examine AF sensitivity in two different renal histological types
with confirmed pathological diagnosis using cells that may more closely represent the human disease.
A total of 13 isolates, from patie ts diagnosed with renal cell carcinoma (clear in 9 and papillary in 4)
were examined for sensitivity to AF.
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These renal cell strains were judged as AF-sensitive if GI50 was < 1 µM and AF resistant if
GI50 > 1 µM. The AF concentration of 1 µM was chosen because it appeared to be achievable following
intravenous administration of AF to preclinical toxicology animal subjects [33]. Seven of the nine
renal cell strains of the clear cell histological type were AF resistant, of which five were very resistant
to AF with a GI50 > 20 µM (Table 1). Two clear cell isolates were AF sensitive with GI50 values of
0.9 µM (cell strain 117) and 0.25 µM (cell strain 109). AF resistance of the majority of the renal cell
strains of the clear cell histological type contrasted with the greater responsiveness of the papillary
histological type to AF. Three of the four renal cell strains exhibiting the papillary histological type had
a GI50 < 1 µM (Table 1). In the 13 cell strains, histology appeared to be somewhat predictive of the
degree of AF sensitivity, as applied to GI50 values for the four papillary cells vs. the nine clear cell
strains. Lower GI50 values were observed in papillary cell strains.
Examination of covalent binding of AF metabolite(s) by these renal cell strains was examined.
(3H)-AF (5-amino-2-(4-amino-3-fluorophenyl)-6,8-difluoro-7-methyl-((3-3H)-4H-1-benzopyran)-4-one)
(specific activity 7.09 Ci/mMol) was used to treat renal tumor cell lines and renal cell strains. Cells were
exposed to 5, 50 and 500 nM AF for 16 h at 37 ◦C in their respective culture medium. Radioactive
medium was removed as described [33]. The varying degrees of sensitivity to AF indicated that most
AF-sensitive cell strains had increased binding of the AF metabolite(s) compared to the AF-resistant
cell strains (Table 1). In 13 cell strains, the degree of covalent binding appeared to be predictive of AF
sensitivity, as applied to values for an AF concentration of 500 nM (1-sided Wilcoxon test p = 0.015).
If one dichotomized the degree of binding (less than 40 K vs. greater than 40 K), high binding occurred
in 4 cell lines: 3 of the 5 sensitive and 1 of the 8 resistant lines. This dichotomization appeared to be
indicative of AF sensitivity (1-sided Fisher’s exact test applied to the 2 × 2 table, p = 0.11).
2.7. AF Sensitivity and Induction of CYP1A1 and CYP1B1 mRNA and Apoptosis in Human Tumor Renal
Cell Strains
Induction of CYP1A1 mRNA following the treatment of renal cell strains was observed in 4 of 5
AF-sensitive strains and in 4 of 8 AF-resistant strains. Induction of CYP1B1 mRNA by AF was apparent
in all AF-sensitive cell strains but in only 1 of 8 AF-resistant strains (see Table 1). Four renal cell strains,
2 clear cell (cell strains 117 and 171) and 2 papillary (112 and 146) histological types exhibited induction
of CYP1A1 and CYP1B1 mRNA following treatment with AF. Three of these strains were sensitive.
Most sensitive renal cell strains were of the papillary histological type.
Studies were also conducted to determine whether AF treatment of the strains exhibiting sensitivity
to AF produces apoptosis, similar to that observed in AF-responsive human tumor renal cell lines.
The five AF-sensitive cell strains demonstrated the highest levels of apoptosis, particularly the three
most sensitive strains of the papillary histological type (146, 132 and 112) and the most AF-sensitive
clear cell type (109). These four AF-sensitive renal cell strains, of which three were of the papillary
histological type, were clearly more susceptible to apoptosis than the remaining nine renal cell strains.
In the 13 cell strains the degree of apoptosis induction appeared to be predictive of AF sensitivity [33]
(1-sided Wilcoxon test, p = 0.002). If one dichotomized the degree of apoptosis induction (less than
2-fold vs. greater than 2-fold), high induction occurred in four cell lines, of which all four were sensitive
lines. This dichotomization appeared to be predictive of AF sensitivity (1-sided Fisher’s exact test
applied to the 2 X 2 table, p = 0.01).
Sensitivity to AF, defined as GI50 < 1 µM, was correlated with covalent binding (dpm/ng cell
protein), CYP1A1 and CYP1B1 mRNA expression (induction relative to control), as well as with
apoptosis induction (relative to the control). All variables were measured at various AF concentrations.
In the 13 renal cell strains, drug sensitivity was also correlated with tumor histology (papillary vs. clear
cell). All results should be considered exploratory and hypothesis-generating rather than conclusive
regardless of the p-values (which are provided for descriptive purposes and were not adjusted for
multiple comparisons). In this context, only p-values < 0.10 should be considered suggestive of
predictive ability for the molecular variable with respect to AF sensitivity.
Int. J. Mol. Sci. 2020, 21, 3551 7 of 20
On the other hand, it should be noted that ability to detect predictive ability for the variables was
severely limited by the small numbers of cell lines and cell strains. The tests used were nonparametric to
avoid making assumptions concerning the statistical distribution of the variables or appropriate scale of
measurement (the tests were invariant under monotonic scale transformations, such as transformation
to logs of the original data). The primary test used was the Wilcoxon rank sum test (a nonparametric
version of the more familiar test), which was used to relate AF sensitivity (a binary categorical
variable) to the magnitudes of the various molecular variables (continuous variables) described.
When appropriate, continuous variables were also dichotomized and related to AF sensitivity by
Fisher’s exact test [38] (a nonparametric version of the more familiar chi-square test). Significance
levels (p-values) are shown as 1- or 2-sided, as appropriate. All p-values were calculated by exact
methods using StatXact-4 (Cytel Software Corp., Cambridge, MA, USA).
Table 1. Renal cell strains were exposed to 0, 1, 10, 100 and 1000 nM AF for 24 h in Dulbecco’s modified
Eagle’s medium containing 4.5 gm/L D-glucose supplemented with 5% fetal calf serum. Cells were
processed, and CYP1A1 and CYP1B1 mRNA was quantitated by RT-PCR. Fold CYP1A1 or CYP1B1
mRNA induction relative to the untreated controls is indicated regarding the AF concentration for
which induction was observed. Cells with high apoptosis are shown (data reported in [33]).
AF nM Concentration (Fold mRNA Induction)
AF resistant Type CYP1A1 mRNA CYP1B1 mRNA Highest apoptosis
115 Clear None None
121 Clear 100 (4), 1000 (82) None
150 Clear None None
151 Clear None None
154 Clear 100 (2) None
171 Clear 100 (2), 1000 (10) 100 (2); 1000 (7)
181 Clear None None
124 Papillary 1, 10, 100, 1000 (2) None
AF sensitive
109 Clear None 1 (4); 10 (2) x
117 Clear 100 (2), 1000 (7) 100 (2); 1000 (5)
112 Papillary 10 (2), 100 (11), 1000 (27) 1, 10 (2); 100 (3); 1000 (7) x
132 Papillary 1, 100, 1000 (2), 10 (9) 1000 (2) x
146 Papillary 1, 10, 100, 1000 (2) 1 (8); 10 (27); 100 (39); 1000 (27) x
The results presented were directly related to early clinical evaluation of the agent. Our data
were concordant with the possibility that tumor cells unable to metabolize the drug will not be
growth inhibited. Hence, the assays described, including CYP1A1 induction following incubation with
unlabeled drug or induction of apoptosis, could be used with tumor biopsies or fine needle aspirates to
select patients with the greater likelihood of benefit, while avoiding the toxicity of drug administration
in patients who have a low likelihood of benefit from the agent. These investigations provided evidence
that sensitivity to AF can be assessed using a combination of covalent binding, induction of CYP1A1
and CYP1B1 mRNA, and susceptibility to apoptosis induction. Furthermore, these results suggest a
trend toward differential sensitivity of renal cell carcinoma histological types to AF, with papillary
renal cell carcinoma exhibiting greater AF sensitivity than clear cell renal cell carcinoma.
2.8. Aryl Hydrocarbon Receptor Activation by Aminoflavone: New Molecular Target for Renal
Cancer Treatment
Considering that AF exhibits noteworthy evidence of antitumor activity in vitro and in vivo
against neoplastic cells of renal origin, inducing CYP1A1, and the covalent binding of the AF-reactive
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intermediates and apoptosis, our research group evaluated the role of AhR, the main transcriptional
regulator of CYP1A1, in the antiproliferative effects of AF in human renal cancer cells. AF-cytotoxicity
in human renal cell lines and a renal cancer cell strain was assessed by MTS assay in the presence
or absence of an AhR inhibitor. Drug-induced AhR nuclear translocation was evaluated by Western
blotting of AhR in cytosolic and nuclear fractions and by measuring xenobiotic response element-driven
luciferase activity. Apoptosis induced by the drug was evaluated by 4,6-diamidino-2-phenylindole
and acridine orange/ethidium bromide staining and by measuring phosphorylated P53 (p-P53) and P21
levels, caspase 3 activation and poly(ADP-ribose) polymerase cleavage. AF inhibited cell growth in a
dose-dependent manner in TK-10, Caki-1, SN12-C and A498 human renal cells, but not in ACHN cells.
The antiproliferative effect of AF was abrogated by preincubation of TK-10, Caki-1 and SN12-C
cells with the AhR antagonist, α-naphthoflavone. AF treatment also induced apoptosis in TK-10, Caki-1
and SN12-C cells, which was not observed in ACHN cells. AF induced time-dependent AhR nuclear
translocation and AhR transcriptional activity in sensitive renal cancer cell lines. A renal cell strain
derived from a human papillary tumor also showed sensitivity to AF, as well as AhR pathway activation
and drug-induced apoptosis. We concluded that AhR translocation could be included as a marker of
sensitivity to AF in sensitive renal tumor cells of different histological origin, in Phase II clinical trials.
Statistical significance between three or more groups was calculated by one-way analysis of
variance (ANOVA) followed by Tukey’s test. To compare two groups, the unpaired Student’s t-test with
a Welch correction was used. Statistical analysis was performed using GraphPad InStat version 3.06
for Windows 95 (GraphPad Software Inc., San Diego, CA, USA; www.graphpad.com). Designations
for statistical significance were * p < 0.05 and ** p < 0.01 [39] (Figure 4).
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2.9. In Vitro Antitumor Effects of AhR Ligand Benzothiazole (5F 203) in Human Renal Cell Carcinoma
Phortress, the lysylamide prodrug of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203),
underwent Phase I clinical evaluation and achieved disease stabilization in 33% of the patients
recruited [40]. Interestingly, preclinical NCI 60 cell line panel data showed that TK-10 cells and other
human renal cancer cell lines were consistently sensitive to 5F 203 and Phortress [41]. Intriguingly,
Phortress stabilized disease in the two renal carcinoma patients recruited to the trial (in one patient,
stability was maintained for 16 cycles). Therefore, we sought to examine AhR pathway activation
and CYP1A1 inducibility in TK-10 and other renal carcinoma cell lines after treatment with 5F 203.
Given the poor prognosis associated with kidney cancer and the paucity of therapeutic options,
preclinical investigations of the use of aminophenylbenzothiazole experimental antitumor agents
against these tumors are warranted.
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2.10. AFP 464 and 5F 203 Altered Cell Cycle Distribution and Evoked Apoptosis in Sensitive Renal
Cancer Cells
As previous results indicate that AFP 464 (NSC710404) induced DNA damage and apoptosis
in renal cancer cells [39] and 5F 203 evoked DNA damage in breast and ovarian cancer cells [34,42],
we investigated perturbations in the cell cycle after treatment of renal cells with these compounds.
For this approach, cells were exposed to 1 µM AFP 464, 1 µM 5F 203 or 0.1%DMSO for 24 and 48 h
and subsequently processed for cell cycle analyses. AFP 464 only caused an increase in phase G0/G1
in TK-10 cells at 24 h. In contrast, the ACHN cell cycle was not perturbed following treatment with
AFP 464. 5F 203 caused an increase in phase G0/G1 in SN12C and Caki-1 and TK-10 cells. In contrast,
the ACHN cell cycle was not perturbed following treatment with 1 µM 5F 203.
A total of 20,000 events were analyzed, and one representative experiment, of three, is shown.
The values represented the average of three independent experiments; * p < 0.05 and ** p < 0.01 with
respect to the control cells [43].
2.11. Impact of AFP 464 and 5F 203 Treatments on Cell Migration
We investigated the effect of AFP 464 and 5F 203 treatments on migration of renal tumor cells
in vitro by wound healing assay. AFP 464 treatment decreased migration neither in the sensitive nor in
the resistant cell lines. In contrast, 5F 203 (1 µM) significantly suppressed cell migration in the three
sensitive cell lines, namely, the TK-10, SN12C and Caki-1 cell lines, respectively. For the non-sensitive
cell line (ACHN), migration was not affected. The AFP 464 wound healing assay was performed as
follows: TK-10, SN12C and ACHN cells were incubated with AFP 464 for 24 h with the dilutions
described in the methodology. A wound was made with a yellow tip; the initial and final wound areas
were measured (Tf = 20 h post wound) and analyzed with the ImageJ program. The graph shows the
percentage migration for each dilution realized. Values that are significantly different from the controls
are indicated (* p < 0.05). Representative fields from one experiment are shown under each graph.
Experiments were performed in triplicate. For the 5F 203 wound healing assay, TK-10, SN12C, Caki-1
and ACHN cells were incubated with 5F 203 for 24 h with the dilutions described in the methodology.
The initial and final wound areas were measured (Tf = 14 h post wound) and analyzed with the
Image J program. The graph shows the percentage migration for each dilution realized. Values that
are significantly different from the controls are indicated (* p < 0.05). Representative fields from one
experiment are shown under each graph. Experiments were performed in triplicate [43].
2.12. Effect of 5F 203 on c-Metphosphorylation in TK-10 Cells
As treatment with 5F 203 demonstrated inhibition of TK-10 cell migration, and p-Met is involved
in the migration process, cell lysates were subjected to p-Met Western blot analyses. TK-10 cells were
exposed to 1 µM 5F 203. Compared to the control, c-Met phosphorylation was downregulated at all
time points examined. Lysates were prepared on three separate occasions; representative phospho
c-Met (pMet), total c-Met (Met) and GAPDH (loading control) blots are shown. Densitometry was
performed on all blots to quantify c-Met, phosphorylated c-Met and GAPDH expression. The pMet/Met,
pMet/GAPDH and Met/GAPDH (D) ratios were calculated. The values represented the average of
three independent experiments; * p < 0.05 and ** p < 0.01 with respect to the control cells.
We concluded that AhR ligand antitumor agents, such as AFP 464 and 5F 203, represent potential
new candidates for the treatment of renal cancer. Both compounds caused cell cycle arrest and apoptosis.
5F 203 is sequestered by TK-10 cells and induces CYP1A1 expression; 5F 203 potently inhibited the
migration of TK-10, Caki-1, and SN12C cells, and inhibited c-Met receptor phosphorylation in TK-10
cells. C-Met receptor signal transduction promotes migration and metastasis. Therefore, we consider
that 5F 203 offers potential for the treatment of metastatic renal carcinoma [43] (Figure 5).
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2.13. Development of Benzothiazole Nanocopounds for Renal Cancer Treatment
As previously described, antitumor benzothiazoles (exemplified by 5F 203, and also
2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610)) demonstrate potent and selective anticancer
activity in vitro and in vivo. As potent AhR ligands, these planar molecules trigger activation of
AhR signal transduction, resulting in their bioactivation by cytochromes P450 (CYPs) 1A1 and
2W1 [44]. The electrophilic products lead to lethal DNA-adduct generation and cancer cell death.
The renal cell line TK-10 has demonstrated sensitivity to this class of antitumor agent and represents
an intractable cancer phenotype for which prognoses are poor. Despite promising activity, the high
lipophilicity and poor aqueous solubility of the benzothiazoles limit their antitumor clinical application.
The apoferritin (AFt) protein cage has been proposed as a robust drug delivery vehicle; it exhibits
stability, is biocompatible, species-specific, non-immunogenic and biodegradable. The AFt capsule
is comprised of 24 polypeptide units that self-assemble into a spherical protein cage; the capsule
possesses channels (0.3–0.4 nm), allowing transport of metal ions, small metal complexes and organic
molecules, and is of uniform size (12 nm with an internal cavity of 8 nm that naturally stores ≤4500
ferric ions). AFt, as a drug delivery vehicle, can lead to increased delivery of the drug to the cancer
tissue via exploitation of the enhanced permeation and retention (EPR) associated with the tumor
microenvironment. AFt is recognized by transferrin receptor-1 (TfR-1; upregulated in cancer cells that
exhibit high iron demand) and internalized into cells via clathrin-coated pit-mediated endocytosis.
It is trafficked through the endosome system, and the pH-dependent disassembly of the AFt capsule in
the acidic lysosomes allows controlled release of the cargo. Thus, we proposed that AFt may represent
a good antitumor benzothiazole delivery vehicle, enhancing aqueous solubility and bioavailability,
promoting the accumulation of the antitumor agent at the tumor sites, potentially improving efficacy
and decreasing potential adverse reactions.
Encapsulation of antitumor benzothiazoles was exhaustively optimized using 5F 203 (Figure 6); [45].
Methods explored included pH- and urea-mediated reassembly and the nanoreactor, diffusion method.
Optimization led to adoption of the nanoreactor method, for AFt encapsulation of 5F 203 and all
subsequent benzothiazoles. HEPES buffer was used and the equivalent of 100 molecules of 5F 203
was added gradually at pH 5.5. In this method, loss of protein and its precipitation were minimized
and encapsulation of ~70 molecules of 5F 203 per AFt cage was achieved (Table 2). Dynamic light
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scattering (DLS) and transmission electron microscopy (TEM; Figure 6b) confirmed that neither AFt size
(13.1± 1.6 nm) nor capsule integrity had been affected by entrapment of 5F 203. Time-of-flight secondary
ion mass spectrometry (ToF-SIMS) was performed, confirming that 5F 203 had been encapsulated
within the AFt interior and was not merely AFt-surface-bound (Figure 6c). A series of distinctive peaks
corresponding to AFt (56–58 m/z) and 5F 203 (255–295 m/z) were detected. With increasing sputter time,
the 25–58 m/z peak intensity diminished and was accompanied by an increased signal in the 255–295 m/z
5F 203 range. Crucially, the 5F 203 and AFt peaks were not concomitantly visible: depth profiling
using an argon cluster beam revealed 5F 203 peaks exclusively below the AFt surface, within the
cavity. Anionic residues on the AFt interior surface bestow on it a net negative charge. To enhance the
encapsulation efficiency of 5F 203, Phortress was encapsulated within AFt. Adopting the optimized
nanoreactor method, ~130 Phortress molecules per AFt cage were achieved. Release of both 5F 203 and
Phortress AFt capsules was complete within 24 h.
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Figure 6. (a) Chemical structures of 5F 203 and Phortress. (b) ToF-SIMS mass spectra of AFt-5F 203.
(c) Summary of intensity change with increasing sputter time. Inset: Transmission electron microscopy
image of AFt-encapsulated 5F 203 and cartoon representation of AFt-5F 203 (figure reproduced
from [46]).
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Table 2. A tabulated summary of GI50 values following treatment of TK10 renal carcinoma cells with
naked- and AFt-encapsulated antitumor benzothiazoles. MTT assays were conducted following 72 h
exposure of cells to test agent. n = 3 per trial; ≥3 independent trials. The mean number of benzothiazole
molecules encapsulated per AFt cage is also depicted.
Benzothiazole
GI50 Value (µM) ± SD
No. Molecules: AFt Cage ± SD
Naked Agent AFt-Encapsulated
5F 203 0.11 ± 0.09 0.028 ± 0.004 71
Phortress 6.3 ± 2.9 0.098 ± 0.008 130
GW 610 0.57 ± 0.16 0.14 ± 0.09 191
GW 608-Lys 34.1 ± 14 0.6 ± 0.35 386
The structurally related dimethoxyphenylbenzothiazole GW 610 (Figure 7) also exhibits potent
and selective antitumor activity against the TK-10 renal cell line. However, its poor pharmaceutical
properties limit applications. Thus, to enhance aqueous solubility and bioavailability, GW 610 was
encapsulated within AFt protein cages [46]; using the nanoreactor method, ~190 molecules of GW 610
per cage were entrapped. A series of amino acid ester prodrugs was synthesized to examine the effect
of polarity and charge on encapsulation. During CYP-catalyzed biotransformation, GW 610 initially
undergoes demethylation to yield 5-fluoro-2-(4-hydroxy-3-methoxyphenyl)benzothiazole (GW 608).
GW 608’s exposed 4-hydroxy group allows conjugation of amino acids via an ester link.
Herein, we focus upon the lysyl–ester GW 608 conjugate. Whereas ~110 molecules of GW 608 were
encapsulated per AFt cage, >380 molecules of GW 608-Lys per AFt cage were entrapped. We concluded
that (i) the increased polarity of GW 608 (compared to GW 610) hinders encapsulation within the
negatively charged cavity; and (ii) charge also impacts encapsulation, and (as in the case for Phortress)
conjugation with positively-charged lysine (GW 608-Lys) resulted in enhanced encapsulation compared
to GW 610, GW 608 and the serine (polar), glycine (non-polar) and aspartic acid (-ve) ester conjugates.
At physiologically relevant temperature (~37 ◦C), 100% release of GW 610 and GW 608-Lys was
observed within 12 h. All encapsulated benzothiazoles were stable at 4 ◦C over a period of >3 months
with respect to drug-loading, as quantified by UV–vis spectroscopy.
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Figure 7. Chemical structures of the GW 610, GW 608 and amino acid prodrugs.
To understand the effect of encapsulation on in vitro antitumour activity of the benzothiazoles,
MTT and clonogenic assays were conducted. In MTT assays, TK10 cells were exposed to the test agent
for 72 h before growth and the test agent growth inhibitory/cytotoxicity were assessed; in clonogenic
assays, clonal survival was assessed following exposure of the cells to the test agents for 24 h. Thereafter,
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the test agent was removed, the cells washed and the medium replenished. Colonies were allowed
to form until they reached a size of ≥50 cells in the control wells. The results of the MTT assays are
summarized in Table 2, and representative dose response curves following exposure of the TK10 cells
to the naked- and AFt-encapsulated GW 610 and Phortress is shown in Figure 8a,c. The AFt vehicle
alone had no effect on cell growth or clonal survival. However, AFt encapsulation of benzothiazole
molecules enhanced their potency against TK10 carcinoma cells: AFt-5F 203 and AFt-GW 610 were
~4-fold more potent; lysyl-derivatives Phortress and GW 608-Lys demonstrated a ~60-fold enhanced
activity following AFt encapsulation. These results were corroborated in clonogenic assays where the
AFt-encapsulated agent inhibited TK-10 survival and colony formation to a greater extent than naked
benzothiazole, as exemplified in the Figure 8c inset. Phortress (administered at GI50 value—6.3 µM)
inhibited colony formation by ~80%, whereas AFt-Phortress (0.1 µM) completely abolished clonal
survival. Both naked- and AFt-GW610 similarly abolished colony formation when administered at
GI50 values (Figure 8a). Importantly, we can conclude that tumor selectivity displayed by 5F 203,
GW 610 and their amino acid prodrugs is maintained following AFt encapsulation. Neither GW 610
nor AFt-GW 610 inhibited growth of benzothiazole-insensitive MRC-5 fibroblasts.
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Figure 8. Representative growth inhibitory dose-response profiles following exposure of (a) and (c)
TK10 carcinoma cells and (b) MRC-5 fibroblasts (72 h) to naked- or AFt-encapsulated (a) and (b) GW610
or (c) Phortress (points are means ± SD, n = 4). Inset in (a) and inset in (c): TK10 clonal survival
following 24 h exposure of cells to naked and AFt-encapsulated GW610 with GI50 values. Data points
are the mean ± SD of 3 independent trials (n = 3 per trial).
We tested the hypothesis that Aft encapsulation may promote more rapid uptake of benzothiazoles
in sensitive tumor cells. 5F 203 and GW 610 rely upon their lipophilic nature to diffuse across cell
membranes before being recognized by cytosolic AhR. The more polar nature of the amino acid
prodrugs may hinder this process, leading to reduced perceived activity compared to parent agents
(as observed in Table 2). However, AFt is sequestered into cells via transferrin recetor-1 (TfR-1)-mediated
endocytosis; TfR-1 is upregulated and highly expressed by cancer cells, including TK-10 [46]. TK-10
cells were seeded (2.5× 105) in 12-well plates and allowed 24 h to attach before being treated with naked-
or AFt-benzothiazole. Following 3 h, 6 h or 9 h exposure periods, cells were harvested and cellular
uptake (of benzothiazole) was determined by flow cytometry. It was evident that AFt encapsulation
potentiate the TK-10 cellular uptake of the benzothiazoles, as exemplified in Figure 9a. After 6 h
and 9 h exposure, intracellular levels of GW 608-Lys were significantly greater (p < 0.01) following
treatment of cells with AFt-GW 608-Lys (compared to naked agent). Intracellular retention of the
benzothiazoles in the benzothiazole-sensitive carcinoma cells is ma e possible by cytosolic AhR,
leading to AhR-signal transduction activation. Indeed, it has been shown that AFt encapsulation
does not affect cytochrome P450 (CYP) 1A1 induction by 5F 203 [45]. This result is in accordance
with the observed release of benzothiazoles from their AFt cages. In insensitive MRC-5 fibroblasts
where TfR-1expression is below detection limits [47] and CYP 1A1 expression is neither constitutive
nor inducible, negligible uptake of benzothiazole molecules is observed, whether delivered naked
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or AFt encapsulated (Figure 9b). This observation is consistent with the selective and potent in vitro
antitumor activity of AFt-encapsulated benzothiazoles.Int. J. Mol. Sci. 2020, 21, x 14 of 20 
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3. Discussion
Previous studies in our research groups have shown that 5F 203 and AF caused growth inhibition
in renal cells, which was accompanied by CYP1A1 induction and apoptosis in sensitive cells.
Both compounds caused cell cycle arrest and apoptosis but only 5F 203 potently inhibited migration
of TK-10, Caki-1 and SN12C cells and the migration signal transduction cascade, involving c-Met,
in TK-10 cells. In our studies, we used a panel of renal cancer cell lines with different von Hippel
Lindau (VHL) statuses [39]. Our results indicated that sensitivity or resistance to AF is independent
of VHL status and HIF expression. This is significant as it widens the variety of renal tumors that
can be effectively treated with this agent. Recently, it has been demonstrated that AF inhibits HIF1α
expression in an AhR-independent fashion in certain breast, renal and ovarian cancer cell lines [48].
In contrast to AFP 464, 5F 203 significantly decreased cell migration in the three sensitive cell
lines. A decrease in wound healing ability was observed in sensitive cell lines, compared to the
control. Consistent with loss of migratory potential, a significant decrease in c-Met phosphorylation
was observed at 1 h in TK-10 cells treated with 1 µM 5F 203. Inhibition of c-Met activity by 5F 203 is
consistent with previous observations: 5F 203 (1 µM; 24 h) decreased c-Met phosphorylation by 85%
and 69 % in MCF-7 and MDA-MB-435 breast carcinoma cells, respectively [49].
We speculate that 5F 203, a potent AhR ligand, triggers activation of a signaling cascade that
potentially inhibits HIF signal transduction and hence the subsequent c-Met activation [49].
However, HIF1α expression after treatment with 5F 203 has to be measured in future studies.
Met signal transduction is a key pathway for the treatment of renal cancer [50] and is also involved in
metastasis progression; therefore, we consider that 5F 203 has potential for the treatment of metastatic
renal carcinoma.
Treatment of sensitive cells with AF caused the translocation of AhR to the nucleus and the
induction of AhR transcriptional activity. In addition, experiments were performed with the renal
cell strain 112, which was derived from a papillary tumor sensitive to AF. These cells also showed
AhR activation by AF, which was in agreement with CYP1A1 induction previously observed in this
renal cell strain. Additionally, we observed AhR nuclear translocation after treatment with the drug.
In our previous report, we indicated that papillary renal tumors are more sensitive to AF than clear
cell tumors [33]. The enhanced activity of AF against the papillary variant of renal cell carcinoma
is of special value. Except for temsirolimus and sunitinib (both have proven their efficacy in the
treatment of non-clear cell kidney cancer and are recommended for clinical use), there are little or
no data regarding the safety and efficacy of the new target drugs in papillary histology and there is
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a need for the development of new effective therapies. However, AhR activation by AF has to be
confirmed in future studies using other papillary and clear cell carcinoma tumors. In contrast to the
other cell lines, ACHN cells showed resistance to AF treatment, which was associated with the lack
of induction of CYP1A1 and CYP1B1 transcription. We demonstrated that AhR activation does not
occur in these cells in response to AF. We hypothesize that this may lead to the lack of activation of
CYP1A1 with the consequent lack of ability of these cells to metabolize AF. In ACHN cells treated with
DMSO only, AhR was present in the cytosol and nucleus. After treatment with 1 µM AF, for 0.5 to
6 h, immunoreactive AhR protein levels do not change in the cytosolic and nuclear fractions. Of note,
we observed high levels of AhR in the nucleus, even in the control, indicating that AhR may be
constitutively nuclear in this cell line. This is a common pattern of AhR subcellular distribution in
cell lines of different origin resistant to AF [33]. A suitable hypothesis may be that nuclear export or
degradation signals may be altered, leading to inappropriate AhR recycling. However, this has to be
tested in future studies. A different AhR variant present in the ACHN cells could explain the fact that
AF does not induce translocation of the receptor in this cell line. Differential expression of proteins that
regulate AhR activation, such as HSP90, may also induce resistance to AF [33].
Since our data are concordant with the thesis that tumor cells that metabolize the drug will exhibit
sensitivity to AF or 5F 203, the assays described, including CYP1A1 induction following incubation
with unlabeled drug or induction of apoptosis, could potentially be performed ex vivo on tumor
biopsies or fine needle aspirates to guide selection of patients with the greatest prospect of treatment
benefit. Such selection would prevent potential toxicity associated with drug administration in patients
who have a low likelihood of treatment benefit. However, according to the current landscape of early
drug development, this may not be a clinical practice reality.
AhR was predominantly expressed in the nuclei of high-grade clear cell RCC (ccRCC) and
tumor-infiltrating lymphocytes (TILs), and its expression levels in cancer cells and TILs correlated with
the pathological tumor stage and histological grade. A multivariate Cox analysis revealed that the
strong expression of AhR in cancer cells was a significant and independent predictor of disease-specific
survival. AhR ligands upregulated the expression of AhR and CYPs and promoted invasion by
upregulating the MMPs. Furthermore, AhR siRNA downregulated CYPs, and inhibited cancer cell
invasion together with the downregulation of the MMPs. These results suggest that AhR regulates the
invasion of ccRCC and may be involved in tumor immunity. Therefore, inhibiting the activation of
AhR may represent a potentially attractive therapeutic target for ccRCC patients [51].
Regarding the AhR and cell cycle progression, it has also been reported that activation of the
AhR by tranilast [52], an antiallergy medication that has demonstrated AhR agonistic activity, resulted
in inhibition of mammosphere formation in drug-surviving cancer stem cells in the triple-negative
breast cancer cell line MDA-MB-231, as well other oncogenic cell lines (BT474, SUM149 and SUM159).
Tranilast also disrupted the interaction of the AhR with CDK4, resulting in cell cycle arrest.
The indole-3-carbinol metabolite, diindoilmetano (DIM), has also demonstrated antitumor activity
mediated by AhR acting on tumor stem cells [53].
On the other hand, omeprazole (OM) is an AhR agonist and a proton-pump inhibitor that is used
to treat people with gastric acid-related diseases [54]. OM as an AhR ligand depends not only on
their structure but also on target organs and downstream reactions and genes. In the classical nuclear
AhR/ARNT-mediated reaction, OM recruited AhR into the region of the c-x-c chemokine receptor 4
(CXCR4) promoter containing XRE, which was accompanied by loss of pol II on the promoter and
decreased expression of CXCR4. Cancer cell CXCR4 overexpression contributes to tumor growth,
invasion, angiogenesis, metastasis, relapse and therapeutic resistance. Therefore, omeprazole inhibits
tumor invasion and regulates metabolism in vivo by inhibiting CXCR4 transcription [55].
Our group has demonstrated that the AF and AF pro-drug (AFP464) disrupt the mammospheres
derived from breast cancer cells and a M05 mammary mouse model of breast cancer, respectively.
We further examined the capacity of AF and AFP464 to exhibit anticancer activity and modulate the
expression of the “stemness” genes, including α6-integrin. AF disrupted the mammospheres and
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prevented secondary mammosphere formation. In contrast, AF did not disrupt the mammospheres
derived from AhR ligand-unresponsive MCF-7 cells. AFP464 treatment suppressed M05 tumor
growth and disrupted the corresponding mammospheres. AF andAFP464 reduced the expression
and percentage of cells that stained for “stemness” markers, including α6-integrin in vitro and
in vivo, respectively. These data suggested AFP464 thwarts bulk breast tumor and TIC growth via
AhR agonist-mediated α6-integrin inhibition [56]. In future studies, it will be important to evaluate
the action of AF and 5F 203 on the tumor stem cell population of renal tumors. Further studies to
evaluate the action of other AhR ligands, such as Tranilast, DIM or omeprazole, on renal cancer stem
cells, also should be performed.
Considering that AhR has recently emerged as a physiological regulator of the innate and adaptive
immune responses, in a previous publication we described that AFP 464 modulates the immune
response in the estrogen-dependent, Tamoxifen-sensitive spontaneous M05 mammary carcinoma model.
Splenic cells and tumor inflammatory infiltrates were studied by cytometric analyses. The modulation
of splenocytes cytotoxic activity by AFP 464 was also evaluated. We further investigated the effects of
AFP 464 on peritoneal macrophages by evaluating metalloproteinase, arginase and iNOS activities.
We found that AFP 464 increased splenic cytotoxic activity, diminished the number of systemic and
local Treg lymphocytes and MDSCs as well as and induced a M1 phenotype in peritoneal macrophages
of M05 tumor-bearing mice. Therefore, we conclude that AFP 464 modulates immune responses, which
collaborates with its anti-tumor activity [57]. Our results place the immune system as a novel target
for this anti-tumor agent. Considering these data, future studies need to elucidate the possible AF
immunomodulation against renal tumors. The effect of 5F 203 on the immune system in these tumors
also should be evaluated. Considering the great impact of the immunomodulators on the treatment of
renal cancer, combination of these AhR ligands with immunotherapy would be an interesting option
to pursue in future studies.
The use of nano-scale drug delivery vehicles in renal cancer also offers an interesting option in
cancer treatment, minimizing toxicity. Our results showed that antitumor benzothiazoles, such as 5F 203
and GW 610, potently inhibit the growth of certain renal carcinoma cells in vitro. These benzothiazoles
are themselves prodrugs, efficiently bioactivated by CYP 1A1 and CYP 2W1 enzymes, whose inducible
or constitutive expression is found in some cancers, including renal cell carcinoma. AFt encapsulation
of 5F 203, GW 610 or their lysine-derivatives provides a robust formulation that enhances aqueous
solubility (and bioavailability), increases intracellular uptake and significantly augments in vitro
antitumor potency, whilst maintaining excellent tumor selectivity. Further in vivo preclinical evaluation
is justified.
Considering that the expression of AhR target genes in the blood, including CYP1A1 and AhRR, is
also upregulated in CKD patients compared to healthy controls [58], in future studies not only fine
needle aspirates from kidney tumors but also blood samples could be used to measure CYP1A1 levels,
as a sensitivity marker, in patients treated with AF or 5F 203. In addition to CYP1A1 induction and
AhR nuclear translocation, other markers of sensitivity to 5F 203 have been identified in ovarian tumors.
5F203 induced enhanced CYP1A1 expression; AhR translocation and reactive species formation (ROS)
in IGROV-1 cells and ascites-isolated ovarian cancer cells that were sensitive to 5F203. In IGROV-1
cells, 5F203-induced ROS formation was accompanied by JNK, ERK and P38MAPK phosphorylation,
as well as DNA damage and cell cycle arrest prior to apoptosis. In contrast, 5F203 failed to induce
CYP1A1 expression, AhR translocation or oxidative stress in 5F203-resistant SKOV-3 cells, or in
ovarian cancer ascites cells inherently resistant to this agent. We developed a bioassay, to measure the
putative biomarkers of sensitivity to this agent that have been proposed using ascites of ovarian cancer
patients [42]. In future studies it could be of interest to measure ROS formation and JNK, ERK and
P38MAPK phosphorylation in renal cancer cells treated ex vivo with 5F 203 as a putative additional
biomarker of renal tumors suitable to be treated with this antitumor agent.
Considering that AhR activation mediates kidney disease and renal cell carcinoma, and that
declining renal function leads to the retention of various metabolites [5] that contributes to a variety
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of diseases, especially chronic kidney disease (CKD) and cardiovascular disease (CVD), as well as
that uremic toxins from tryptophan metabolites that activate AhR contribute to these diseases, uremic
toxins may provide new potential therapeutic approaches targeting AhR activation. Therefore, further
studies should be performed on the effect of novel metabolites on AhR activity. AF and 5F 203 may
only represent a fraction of the AhR ligands possessing potential therapeutic effects in renal cancer.
Other metabolites with therapeutic actions derived from nutraceuticals, such as flavonoids, may be
found in the near future.
In conclusion, AF and 5F 203 represent experimental anticancer agents that target novel molecular
targets pertinent to renal cell carcinoma: AhR, CYP 1A1 and CYP 2W1. The mechanism of action,
distinct from current clinical pharmacopeia, offers pharmacodynamics biomarkers of sensitivity that
could guide patient selection.
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